Clinical perspectives of bispecific antibodies in cancer

被引：16

作者：

deGast, GC

vandeWinkel, JGJ

Bast, BEJEG

机构：

[1] UNIV UTRECHT, DEPT IMMUNOL, UTRECHT, NETHERLANDS

[2] UNIV UTRECHT, MEDAREX EUROPE, UTRECHT, NETHERLANDS

来源：

CANCER IMMUNOLOGY IMMUNOTHERAPY | 1997年 / 45卷 / 3-4期

关键词：

D O I：

10.1007/s002620050412

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：121 / 123

页数：3

共 19 条

[1] REGRESSION OF ADVANCED OVARIAN-CARCINOMA BY INTRAPERITONEAL TREATMENT WITH AUTOLOGOUS T-LYMPHOCYTES RETARGETED BY A BISPECIFIC MONOCLONAL-ANTIBODY
CANEVARI, S
STOTER, G
ARIENTI, F
BOLIS, G
COLNAGHI, MI
DIRE, EM
EGGERMONT, AMM
GOEY, SH
GRATAMA, JW
LAMERS, CHJ
NOOY, MA
PARMIANI, G
RASPAGLIESI, F
RAVAGNANI, F
SCARFONE, G
TRIMBOS, JB
WARNAAR, SO
BOLHUIS, RLH
[J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1995, 87 (19): : 1463 - 1469
[2] CD8 T-CELL ACTIVATION AFTER INTRAVENOUS ADMINISTRATION OF CD3XCD19 BISPECIFIC ANTIBODY IN PATIENTS WITH NON-HODGKIN-LYMPHOMA
DEGAST, GC
HAAGEN, IA
VANHOUTEN, AA
KLEIN, SC
DUITS, AJ
DEWEGER, RA
VROOM, TM
CLARK, MR
PHILLIPS, J
VANDIJK, AJG
DELAU, WBM
BAST, BJEG
[J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 1995, 40 (06) : 390 - 396
[3] Bispecific antibody-mediated immunotherapy of the BCL(1) lymphoma: Increased efficacy with multiple injections and CD28-induced costimulation
Demanet, C
Brissinck, J
DeJonge, J
Thielemans, K
[J]. BLOOD, 1996, 87 (10) : 4390 - 4398
[4] Clinical significance of IgG Fc receptors and Fc gamma R-directed immunotherapies
Deo, YM
Graziano, RF
Repp, R
vandeWinkel, JGJ
[J]. IMMUNOLOGY TODAY, 1997, 18 (03): : 127 - 135
[5] HLA class II as potential target antigen on malignant B cells for therapy with bispecific antibodies in combination with granulocyte colony-stimulating factor
Elasser, D
Valerius, T
Repp, R
Weiner, GJ
Deo, Y
Kalden, JR
vandeWinkel, JGJ
Stevenson, GT
Glennie, MJ
Gramatzki, M
[J]. BLOOD, 1996, 87 (09) : 3803 - 3812
[6] Fanger NA, 1996, J IMMUNOL, V157, P541
[7] GUYRE PM, 1989, J IMMUNOL, V143, P1650
[8] Treatment of refractory Hodgkin's disease with an anti-CD16/CD30 bispecific antibody
Hartmann, F
Renner, C
Jung, W
Deisting, C
Juwana, M
Eichentopf, B
Kloft, M
Pfreundschuh, M
[J]. BLOOD, 1997, 89 (06) : 2042 - 2047
[9] PHASE-I STUDY OF INTRAVENOUSLY APPLIED BISPECIFIC ANTIBODY IN RENAL-CELL CANCER-PATIENTS RECEIVING SUBCUTANEOUS INTERLEUKIN-2
KROESEN, BJ
BUTER, J
SLEIJFER, DT
JANSSEN, RAJ
VANDERGRAAF, WTA
THE, TH
DELEIJ, L
MULDER, NH
[J]. BRITISH JOURNAL OF CANCER, 1994, 70 (04) : 652 - 661
[10] A SMALL BISPECIFIC ANTIBODY CONSTRUCT EXPRESSED AS A FUNCTIONAL SINGLE-CHAIN MOLECULE WITH HIGH TUMOR-CELL CYTOTOXICITY
MACK, M
RIETHMULLER, G
KUFER, P
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (15) : 7021 - 7025

← 1 2 →